Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INPULSIS-ON: Long-Term Safety of Nintedanib in IPF Extension
NCT01619085Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2012
- Primary completion
- Jul 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 24
01
Overview
A Phase 3 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Jun 2012; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01619085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619085.